GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007124110 | Prostate | BPH | cellular response to inorganic substance | 62/3107 | 226/18723 | 2.57e-05 | 3.05e-04 | 62 |
GO:00364994 | Prostate | BPH | PERK-mediated unfolded protein response | 11/3107 | 18/18723 | 2.62e-05 | 3.10e-04 | 11 |
GO:007005917 | Prostate | BPH | intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress | 24/3107 | 63/18723 | 3.48e-05 | 3.87e-04 | 24 |
GO:00459473 | Prostate | BPH | negative regulation of translational initiation | 11/3107 | 19/18723 | 5.28e-05 | 5.42e-04 | 11 |
GO:00364902 | Prostate | BPH | regulation of translation in response to endoplasmic reticulum stress | 8/3107 | 11/18723 | 5.85e-05 | 5.90e-04 | 8 |
GO:00181059 | Prostate | BPH | peptidyl-serine phosphorylation | 79/3107 | 315/18723 | 7.09e-05 | 6.96e-04 | 79 |
GO:00435583 | Prostate | BPH | regulation of translational initiation in response to stress | 9/3107 | 14/18723 | 8.47e-05 | 8.03e-04 | 9 |
GO:00480093 | Prostate | BPH | insulin-like growth factor receptor signaling pathway | 16/3107 | 37/18723 | 1.22e-04 | 1.10e-03 | 16 |
GO:19909282 | Prostate | BPH | response to amino acid starvation | 19/3107 | 49/18723 | 1.70e-04 | 1.46e-03 | 19 |
GO:00182097 | Prostate | BPH | peptidyl-serine modification | 82/3107 | 338/18723 | 1.73e-04 | 1.48e-03 | 82 |
GO:00341982 | Prostate | BPH | cellular response to amino acid starvation | 18/3107 | 46/18723 | 2.19e-04 | 1.78e-03 | 18 |
GO:19022357 | Prostate | BPH | regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway | 14/3107 | 32/18723 | 2.77e-04 | 2.16e-03 | 14 |
GO:01404673 | Prostate | BPH | integrated stress response signaling | 11/3107 | 22/18723 | 3.03e-04 | 2.34e-03 | 11 |
GO:007124810 | Prostate | BPH | cellular response to metal ion | 52/3107 | 197/18723 | 3.13e-04 | 2.39e-03 | 52 |
GO:00069832 | Prostate | BPH | ER overload response | 8/3107 | 13/18723 | 3.33e-04 | 2.52e-03 | 8 |
GO:0042149 | Prostate | BPH | cellular response to glucose starvation | 18/3107 | 48/18723 | 4.06e-04 | 2.96e-03 | 18 |
GO:00018199 | Prostate | BPH | positive regulation of cytokine production | 105/3107 | 467/18723 | 5.18e-04 | 3.66e-03 | 105 |
GO:00519604 | Prostate | BPH | regulation of nervous system development | 100/3107 | 443/18723 | 6.02e-04 | 4.16e-03 | 100 |
GO:00069195 | Prostate | BPH | activation of cysteine-type endopeptidase activity involved in apoptotic process | 24/3107 | 78/18723 | 1.39e-03 | 8.31e-03 | 24 |
GO:00070293 | Prostate | BPH | endoplasmic reticulum organization | 26/3107 | 87/18723 | 1.45e-03 | 8.61e-03 | 26 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0501228 | Prostate | BPH | Parkinson disease | 143/1718 | 266/8465 | 1.19e-34 | 3.94e-32 | 2.44e-32 | 143 |
hsa0502026 | Prostate | BPH | Prion disease | 141/1718 | 273/8465 | 1.11e-31 | 1.23e-29 | 7.58e-30 | 141 |
hsa0414128 | Prostate | BPH | Protein processing in endoplasmic reticulum | 97/1718 | 174/8465 | 2.37e-25 | 1.30e-23 | 8.07e-24 | 97 |
hsa0501026 | Prostate | BPH | Alzheimer disease | 165/1718 | 384/8465 | 4.03e-25 | 1.66e-23 | 1.03e-23 | 165 |
hsa0501426 | Prostate | BPH | Amyotrophic lateral sclerosis | 151/1718 | 364/8465 | 3.37e-21 | 1.01e-19 | 6.25e-20 | 151 |
hsa0493226 | Prostate | BPH | Non-alcoholic fatty liver disease | 83/1718 | 155/8465 | 2.49e-20 | 6.32e-19 | 3.91e-19 | 83 |
hsa0502226 | Prostate | BPH | Pathways of neurodegeneration - multiple diseases | 180/1718 | 476/8465 | 7.70e-20 | 1.81e-18 | 1.12e-18 | 180 |
hsa0421016 | Prostate | BPH | Apoptosis | 46/1718 | 136/8465 | 1.41e-04 | 8.31e-04 | 5.14e-04 | 46 |
hsa0541728 | Prostate | BPH | Lipid and atherosclerosis | 66/1718 | 215/8465 | 1.68e-04 | 9.56e-04 | 5.92e-04 | 66 |
hsa0413726 | Prostate | BPH | Mitophagy - animal | 28/1718 | 72/8465 | 2.12e-04 | 1.13e-03 | 6.98e-04 | 28 |
hsa051607 | Prostate | BPH | Hepatitis C | 48/1718 | 157/8465 | 1.36e-03 | 5.85e-03 | 3.62e-03 | 48 |
hsa051624 | Prostate | BPH | Measles | 42/1718 | 139/8465 | 3.35e-03 | 1.23e-02 | 7.61e-03 | 42 |
hsa041408 | Prostate | BPH | Autophagy - animal | 42/1718 | 141/8465 | 4.46e-03 | 1.53e-02 | 9.49e-03 | 42 |
hsa05012112 | Prostate | BPH | Parkinson disease | 143/1718 | 266/8465 | 1.19e-34 | 3.94e-32 | 2.44e-32 | 143 |
hsa05020111 | Prostate | BPH | Prion disease | 141/1718 | 273/8465 | 1.11e-31 | 1.23e-29 | 7.58e-30 | 141 |
hsa04141112 | Prostate | BPH | Protein processing in endoplasmic reticulum | 97/1718 | 174/8465 | 2.37e-25 | 1.30e-23 | 8.07e-24 | 97 |
hsa05010111 | Prostate | BPH | Alzheimer disease | 165/1718 | 384/8465 | 4.03e-25 | 1.66e-23 | 1.03e-23 | 165 |
hsa05014111 | Prostate | BPH | Amyotrophic lateral sclerosis | 151/1718 | 364/8465 | 3.37e-21 | 1.01e-19 | 6.25e-20 | 151 |
hsa04932111 | Prostate | BPH | Non-alcoholic fatty liver disease | 83/1718 | 155/8465 | 2.49e-20 | 6.32e-19 | 3.91e-19 | 83 |
hsa05022111 | Prostate | BPH | Pathways of neurodegeneration - multiple diseases | 180/1718 | 476/8465 | 7.70e-20 | 1.81e-18 | 1.12e-18 | 180 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EIF2AK3 | SNV | Missense_Mutation | novel | c.1153A>C | p.Ser385Arg | p.S385R | Q9NZJ5 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-A2-A0CO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | CR |
EIF2AK3 | SNV | Missense_Mutation | novel | c.2068A>G | p.Met690Val | p.M690V | Q9NZJ5 | protein_coding | tolerated(0.57) | benign(0.001) | TCGA-A8-A09E-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD |
EIF2AK3 | SNV | Missense_Mutation | | c.341N>T | p.Arg114Ile | p.R114I | Q9NZJ5 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EIF2AK3 | SNV | Missense_Mutation | | c.3150N>T | p.Glu1050Asp | p.E1050D | Q9NZJ5 | protein_coding | deleterious(0.01) | probably_damaging(0.979) | TCGA-AN-A0FJ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
EIF2AK3 | SNV | Missense_Mutation | novel | c.910N>T | p.Ala304Ser | p.A304S | Q9NZJ5 | protein_coding | tolerated(0.4) | benign(0) | TCGA-LL-A73Z-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
EIF2AK3 | insertion | In_Frame_Ins | novel | c.2065_2066insATGAGGACATCAGTGAGT | p.Pro689delinsHisGluAspIleSerGluSer | p.P689delinsHEDISES | Q9NZJ5 | protein_coding | | | TCGA-A8-A09E-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD |
EIF2AK3 | insertion | Frame_Shift_Ins | novel | c.1169_1170insAAAATATAAA | p.Met390IlefsTer6 | p.M390Ifs*6 | Q9NZJ5 | protein_coding | | | TCGA-AC-A3QQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
EIF2AK3 | insertion | Nonsense_Mutation | novel | c.2848_2849insGTTATTAGCATATCCAAGGTATCAAACT | p.Val950GlyfsTer3 | p.V950Gfs*3 | Q9NZJ5 | protein_coding | | | TCGA-AN-A0FN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
EIF2AK3 | insertion | Frame_Shift_Ins | novel | c.1492_1493insATGAGAAAGA | p.Val498AspfsTer62 | p.V498Dfs*62 | Q9NZJ5 | protein_coding | | | TCGA-AR-A0U2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | PD |
EIF2AK3 | insertion | Frame_Shift_Ins | novel | c.3241_3242insG | p.Asp1081GlyfsTer31 | p.D1081Gfs*31 | Q9NZJ5 | protein_coding | | | TCGA-B6-A0IN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
9451 | EIF2AK3 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME | | Indoline derivative 7 | | |
9451 | EIF2AK3 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME | inhibitor | 336446930 | | |
9451 | EIF2AK3 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME | | Indoline derivative 3 | | |
9451 | EIF2AK3 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME | | Phenylpyrrolidinone derivative 1 | | |
9451 | EIF2AK3 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME | | Tricyclic isoxazoloquinazoline derivative 3 | | |
9451 | EIF2AK3 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME | | Indoline derivative 8 | | |
9451 | EIF2AK3 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME | | Tricyclic isoxazoloquinazoline derivative 1 | | |
9451 | EIF2AK3 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME | inhibitor | 178103351 | CHEMBL2171124 | |
9451 | EIF2AK3 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME | | Phenylpyrrolidinone derivative 5 | | |
9451 | EIF2AK3 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME | | Indoline derivative 10 | | |